Skip to main content
PRESCIENT THERAPEUTICS LIMITED logo

PRESCIENT THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PTX ISIN · AU000000PTX3 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,006 across all filing types
Latest filing 2019-03-24 Capital/Financing Update
Country AU Australia
Listing ASX PTX

About PRESCIENT THERAPEUTICS LIMITED

https://ptxtherapeutics.com/

Prescient Therapeutics Limited is a clinical-stage oncology company focused on developing personalized medicine and innovative cancer treatments. The company leverages two primary technology pillars: modular cell therapies and targeted small molecule inhibitors. Its flagship OmniCAR platform is a universal, multi-arm CAR-T system designed to provide clinicians with enhanced control and flexibility over cell therapy treatments, addressing limitations such as antigen escape and toxicity. Complementing this is the CellPryme platform, which optimizes cell therapy performance through improved manufacturing and efficacy. Additionally, Prescient maintains a pipeline of targeted therapies, including PTX-100, a first-in-class prenylation inhibitor targeting the Ras pathway, and PTX-200, an AKT inhibitor. These programs aim to treat various hematological malignancies and solid tumors by addressing specific genetic drivers of cancer.

Recent filings

Filing Released Lang Actions
Prescient Completes Equity Raising to Raise $9.1 Million 6 pages 237.7KB
Capital/Financing Update Classification · 95% confidence The document is an ASX release announcing the completion of an equity raising totaling $9.1 million, consisting of a placement and a non-renounceable rights issue. It details the number of shares and options to be issued, use of funds, key dates, and other information related to the capital raising. There are no financial statements or detailed financial performance data included. The document is clearly an update on the company's capital raising activities and financing structure. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial and contains detailed information about the financing but does not constitute a full financial report or earnings release.
2019-03-24 English
Capital Raising Presentation - March 2019 36 pages 1.4MB
Capital/Financing Update Classification · 95% confidence The document is titled 'CAPITAL RAISING PRESENTATION MARCH 2019' and contains detailed information about a capital raising effort by Prescient Therapeutics Limited, including the amount being raised, the use of proceeds, and terms of the offer. It includes forward-looking statements, disclaimers, and detailed financial and clinical program information relevant to investors. The document is a presentation format aimed at investors to inform them about the capital raising and the company's clinical pipeline and financial position. It is not a formal financial report, earnings release, or regulatory filing, but rather a detailed investor presentation focused on financing activities and company strategy. Therefore, the most appropriate classification is 'Capital/Financing Update' (CAP). The document length (15,000 characters) and content confirm it is not a brief announcement or a report publication announcement, but a full presentation.
2019-03-24 English
Prospectus 47 pages 611.1KB
Capital/Financing Update Classification · 95% confidence The document is titled 'Prospectus' and relates to a fully underwritten non-renounceable pro rata entitlement offer of new shares and options by Prescient Therapeutics Limited. It includes detailed information about the offer, terms, legal notices, and instructions for shareholders. The content focuses on raising capital through issuing new shares and options, which is a financing activity. There is no indication that this is an annual report, earnings release, or any other type of report. The document is lengthy (15,000 characters) and contains substantive information about the capital raising. Therefore, the document fits the category of a Capital/Financing Update (CAP).
2019-03-24 English
Appendix 3B - Rights Issue 12 pages 182.5KB
Capital/Financing Update Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and contains detailed information about a new issue of securities, including the class of securities, number of securities issued, issue price, purpose of the issue, underwriting details, and quotation application. It references ASX rules and is structured as a formal announcement for the issuance and quotation of additional securities. This matches the description of a Capital/Financing Update, which covers company fundraising and capital structure changes. The document is not a full financial report, earnings release, or regulatory filing but a specific announcement about a new share issue and related securities.
2019-03-24 English
Letter to Eligible Shareholders 3 pages 89.6KB
Capital/Financing Update Classification · 95% confidence The document is a detailed notice to shareholders about an entitlement offer, describing the terms, eligibility, timetable, and procedural details of a capital raising event involving new share issuance and options. It includes information about the placement, underwriting, and prospectus dispatch. The content focuses on informing shareholders about the capital raising and how they can participate, which aligns with announcements related to financing activities and capital structure changes. There are no financial statements or performance data, so it is not an Annual Report or Interim Report. It is not a proxy, voting result, or management report. The document is not a regulatory filing or a report publication announcement but a substantive announcement of a capital raising event. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2019-03-24 English
Letter to Ineligible shareholders 2 pages 110.3KB
Capital/Financing Update Classification · 95% confidence The document is a letter dated 25 March 2019 from Prescient Therapeutics Limited to shareholders, specifically addressing an entitlement offer and placement to raise capital. It details the terms of the entitlement offer, eligibility criteria for shareholders, and the underwriting agreement. The content focuses on a capital raising event, including share issuance terms and underwriting, rather than financial results or management commentary. There is no financial statement or detailed financial analysis present, nor is it a regulatory certification or announcement of a report publication. The document is clearly an update on financing activities, specifically an equity raising through placement and entitlement offer. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is sufficient and the content matches the CAP category well, so confidence is high.
2019-03-24 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.